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Abstract The effect of direct phosphorylation by recombinant
p44erk1 mitogen-activated protein kinase on the inhibitory
activity of caldesmon and its C-terminal fragment H1 was
studied in vitro. Neither inhibition of actin-tropomyosin activated
ATPase of heavy meromyosin by caldesmon or H1, nor
inhibition of the actin-tropomyosin motility over heavy mer-
omyosin by H1 was significantly affected by the phosphorylation
while only a moderate effect on the actin-activated component of
heavy meromyosin ATPase inhibition was observed. Phospho-
peptide mapping of caldesmon immunoprecipitated from
[32P]PO4-labelled intact gizzard strips revealed that it is
predominantly phosphorylated at mitogen-activated protein
kinase sites in unstimulated tissue and that it is stimulated for
1 h with phorbol 12,13-dibutyrate. We find that phorbol 12,13-
dibutyrate also induces a transitory phosphorylation of caldes-
mon peaking at 15 min after addition and this phosphorylation is
not attributed to mitogen-activated protein kinase, protein kinase
C, Ca2/calmodulin-dependent kinase II or casein kinase II. We
suggest that a yet unidentified kinase, rather than mitogen-
activated protein kinase, may be involved in regulation of the
caldesmon function in vivo.
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1. Introduction
Caldesmon is an actin-associated regulatory component of
smooth muscle which provides a negative control of actomyo-
sin-based contractility [1,2]. In vitro, it potently inhibits acto-
tropomyosin-activated ATPase of smooth and skeletal muscle
myosin and actin ¢lament movement over myosin in the in
vitro motility assay [3^5]. Exogenous caldesmon inhibits force
production and promotes relaxation of skinned smooth
muscles [6^8], yet, its functionally active fragments produce
similar e¡ects on skinned ¢bers [9] and isolated smooth
muscle cells [10,11]. The modulatory function of caldesmon
has recently been supported by its antisense knockout in
smooth muscle in situ [12].
Since caldesmon was found as a phosphoprotein in smooth
muscle, the phosphorylation has been suggested to regulate its
functional activity (reviewed in [13]). The level of caldesmon
phosphorylation was found to alter upon tissue stimulation
with various contractile agonists [14^16] and attempts have
been made to identify the kinases involved in caldesmon phos-
phorylation in vivo. On the basis of sequence identity of phos-
phopeptides of caldesmon isolated from arterial tissue to the
sites phosphorylated in puri¢ed protein by p42/p44erk mito-
gen-activated protein (MAP) kinases (hereafter referred to
simply as MAP kinase), MAP kinase was identi¢ed as in
vivo caldesmon kinase responsive to phorbol 12,13-dibutyrate
(PDBu) stimulation [17,18]. Other stimulants as well as mem-
brane depolarization were also shown to result in MAP kinase
activation [19] and caldesmon phosphorylation at correspond-
ing sites [14]. These studies led to a verdict that MAP kinase is
the predominant, if not sole, caldesmon kinase in smooth
muscle.
Although apparently physiologically relevant, the direct
consequences of caldesmon phosphorylation by MAP kinase
are rather uncertain. In vitro, it had moderate, if any, e¡ects
on binding abilities of caldesmon [20], while the inhibitory
activity of the bacterially expressed caldesmon fragment was
reduced after mutation of the MAP kinase phosphorylation
site to mimic phosphorylation [21]. However, phosphorylation
of endogenous caldesmon in skinned smooth muscle by exog-
enous MAP kinase neither induced contraction nor a¡ected
the Ca2-sensitivity [22] and had marginal e¡ects in airway
smooth muscle [23]. Speci¢c inhibition of intracellular MAP
kinase by PD098059 almost to a basal level failed to alter the
vascular contractility [24], yet, the phosphorylation of caldes-
mon was only slightly decreased [25].
In the present study, we re-addressed this issue by demon-
strating that MAP kinase does not exert a large regulatory
e¡ect on the caldesmon function in vitro and is not the only
caldesmon kinase in smooth muscle. In view of the results
obtained, we propose that kinase(s) other than MAP kinase
are rather involved in regulation of the caldesmon function in
vivo.
2. Materials and methods
2.1. Materials
[Q-32P]ATP and [32P]trisodium orthophosphate were from the Insti-
tute of Physics and Energetics (Obninsk, Russia). PDBu was pur-
chased from Sigma and protein G-agarose from Calbiochem. BL21
DE3 Escherichia coli strains were obtained from Gibco BRL. Okadaic
acid was from LC Laboratories, biological bu¡ers and chemicals were
from Sigma or BDH.
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2.2. Tissue labelling and caldesmon phosphorylation in situ
Muscle slices (6U4U0.6 mm) were cut across the long axis of the
larger chicken gizzard body, so that ¢ber bundles were aligned longi-
tudinally. The strips were incubated in three changes of phosphate-
free minimal essential medium (Gibco) for 1.5 h at 37‡C with contin-
uous carbogen administration. Then, medium was replaced for 4 h
with HBSS containing 20 mM HEPES, pH 7.4, and 0.125^0.25 mCi/
ml of [32P]Na3PO4. After addition of 2 WM PDBu, individual strips
were removed at appropriate times, rinsed with ice-cold HBSS and
frozen in liquid nitrogen. The tissue was pulverized while frozen and
homogenized in ice-cold 20 mM MOPS, pH 7.0, 1% Triton X-100,
0.35 M NaCl, 25 mM MgCl2, 2 mM EGTA, 1 mM dithiothreitol,
1 mM o-vanadate and a protease inhibitor cocktail. Caldesmon was
immunoprecipitated from clari¢ed extracts by 15^25 Wg of anti-chick-
en gizzard caldesmon polyclonal antibody [26] absorbed to protein G-
agarose and subjected to SDS-PAGE in duplicate on separate gels.
Following autoradiography, the relative level of caldesmon phospho-
rylation was calculated as a ratio of values obtained by scanning
autoradiograms and Coomassie-stained gels, respectively. Gel pieces
containing 32P-labelled caldesmon were excised and extensively di-
gested with TPCK-treated trypsin (Worthington Biochem. Corp.)
[27]. The digest was lyophilized, dissolved in thin layer electrophoresis
bu¡er (acetic acid/formic acid/H2O, 15:5:80) and run on SilicaGel 60
20U20 cm plates (Merck) at 1000 V for 75 min at 10‡C in the ¢rst
dimension, followed by ascending chromatography in n-butanol/pyr-
idine/acetic acid/H2O (150:150:40:160) in the second dimension.
Phosphopeptides were visualized by autoradiography on a Kodak
Biomax ¢lm.
2.3. MAP kinase expression and activation
p44erkl MAP kinase cDNA cloned into the pGEX-3X vector was a
gift from Dr T. Voyno-Yasenetskaya (Chicago University, IL, USA).
The kinase was expressed in BL21 DE3 E. coli cells and puri¢ed using
the glutathione S-transferase (GST) puri¢cation module (Pharmacia
Biotech). To activate GST-MAP kinase in vitro, serum-deprived sub-
con£uent COS-7 cells grown on DMEM (Gibco) were stimulated for
10 min with 50 nM epidermal growth factor and activated MAP
kinase (MEK) was immunoprecipitated within 3 h by anti-MEK
1p2 antibody (Transduction Laboratories) bound to protein G-agar-
ose. GST-MAP kinase was activated by phosphorylation with the
MEK immunocomplex and stored at 320‡C in 50% glycerol.
2.4. Proteins and phosphorylation in vitro
Chicken gizzard caldesmon [28] and sheep aorta tropomyosin [29]
were isolated as described. C-terminal caldesmon fragment H1 was
expressed in BL21 DE3 cells and puri¢ed as in [29]. Rabbit skeletal
muscle actin was puri¢ed from acetone powder according to [30] and
HMM was prepared as in [31]. Casein kinase II (CK2) was isolated
from rabbit liver [32], Ca2/calmodulin-dependent protein kinase II
(CaMKII) was obtained from New England Biolabs and protein kin-
ase C (PKC)-L1/L2 was a gift from D.L. Silver and Dr J.R. Sellers
(NHLBI, NIH, USA). Phosphorylation by these kinases was per-
formed as described [32]. Phosphorylation of 0.65 mg/ml caldesmon
or H1 by 0.03 mg/ml GST-MAP kinase was carried out at 30‡C for 2 h
in the presence of 0.2 mM ATP and terminated by heating to 60^70‡C
to inactivate the kinase. Usually, around 1 mol of phosphate was
incorporated per mol protein as determined with [Q-32P]ATP by ¢lter
counting [32]. Comparative phosphorylation of a panel of recombi-
nant caldesmon fragments revealed that the phosphorylation sites of
caldesmon are conserved within H1 (data not shown). Protein con-
centrations were determined by either using the following optical ex-
tinction coe⁄cients, caldesmon, A1%280 = 3.03, G-actin, A
1%
280 = 0.63, or
by the Lowry method as in [3,4].
2.5. In vitro motility and ATPase assay
Actin-tropomyosin motility over heavy meromyosin (HMM) was
assayed as in [4] at 27‡C in the bu¡er containing 40 mM KCl,
25 mM imidazol-HCl, pH 7.4, 1 mM ATP, 4 mM MgCl2, 1 mM
EDTA, 5 mM dithiothreitol, 0.5% methylcellulose, 3 mg/ml glucose,
0.1 mg/ml glucose oxidase and 0.02 mg/ml catalase. The number of
motile ¢laments and their velocities were calculated as outlined [33].
ATPase of 2 WM skeletal muscle HMM was assayed with 10 WM
skeletal muscle actin with or without 2.3 WM sheep aorta tropomyosin
at 37‡C in 5 mM Pipes/KOH (pH 7.1), 5 mM MgCl2, 50 mM KCl,
3 mM MgATP and 0.1 mM dithiothreitol as described [3].
3. Results
3.1. Phosphorylation by MAP kinase does not a¡ect inhibition
of the actomyosin interaction by caldesmon
Caldesmon and its fully functional bacterially expressed
C-terminal fragment H1 showed an equipotent inhibition of
actin-tropomyosin activated HMM ATPase (Fig. 1). Phos-
phorylation by recombinant MAP kinase (V1 mol Pi/mol)
had no e¡ect on their inhibitory activity at low caldesmon
or H1 ratios to actin suggesting that tropomyosin-dependent
inhibition is una¡ected by the phosphorylation. At higher
ratios of caldesmon or H1 to actin, a little de-inhibition
brought by the phosphorylation was observed (Fig. 1). Con-
sistently, a somewhat stronger e¡ect of phosphorylation on
caldesmon or H1 inhibition of actin-activated ATPase was
obtained in the absence of tropomyosin (Fig. 1, insert), which
supports earlier ¢ndings [20] that phosphorylation by MAP
kinase slightly a¡ects the actin-binding a⁄nity of caldesmon.
Because H1 retains the inhibitory and actin-binding ca-
pacity of caldesmon [29], it was used to inhibit the sliding
of actin-tropomyosin ¢laments over HMM in in vitro motility
assay. Using an automatic tracking programme described ear-
lier [33], only a small reduction (up to 20%) in the ¢lament
velocity upon H1 addition was detected while this inhibition
was not observed with phosphorylated H1 (data not shown).
In agreement with our previous data, H1 strongly decreased
the number of motile ¢laments [4], while phosphorylation of
H1 by MAP kinase partially reversed this switching o¡ the
motility (Fig. 2). However, phosphorylation produced almost
no di¡erence in inhibition at low concentrations of H1 (5 WM)
while the increasing amounts of phosphorylated H1 produced
little further inhibition in contrast to the unphosphorylated
fragment which inhibited in a clear dose-dependent manner.
We suggest that, as in the ATPase assay, phosphorylation by
MAP kinase relieves inhibition mediated by a low a⁄nity
Fig. 1. The e¡ect of caldesmon and H1 phosphorylation by MAP
kinase on the inhibition of actin-tropomyosin or actin (the insert)-
activated HMM ATPase. Inhibition by caldesmon (CD, open
circles) and H1 (open triangles) was compared to that by phos-
phorylated caldesmon (P-CD, closed circles) or phosphorylated H1
(P-H1, closed triangles). The uninhibited acto-tropomyosin-HMM
ATPase rate was 2.2 sec31 and that for acto-HMM was 0.85 sec31.
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interaction of caldesmon or H1 with actin while the physio-
logically relevant, high a⁄nity tropomyosin-dependent inhib-
ition is rather una¡ected.
3.2. Caldesmon kinases stimulated by phorbol ester in intact
gizzard smooth muscle
To avoid non-speci¢c stimulation of endogenous MAP kin-
ase by mechanical stress [34], caldesmon phosphorylation was
studied in unloaded strips of chicken gizzard metabolically
labelled with [32P]phosphate. Caldesmon was speci¢cally im-
munoprecipitated from tissue extracts (Fig. 3A, left panel) by
a⁄nity-puri¢ed polyclonal antibody which equally recognizes
both phosphorylated and unphosphorylated protein (data not
shown). PDBu induced a rapid increase in caldesmon phos-
phorylation with the maximum at 10^25 min after addition.
Then, the level of caldesmon phosphorylation declined and
rose again after 60^90 min of continuous stimulation with
PDBu (Fig. 3A, right panel). PDBu induced an about 2-fold
maximum increase in caldesmon phosphorylation as assessed
by scanning densitometry, in agreement with the data re-
ported for other smooth muscles [14,16,23,35].
To investigate whether the biphasic nature of caldesmon
phosphorylation is due to the distinct kinases involved, two
dimensional phosphopeptide maps were generated from 32P-
labelled caldesmon immunoprecipitated from unstimulated
Fig. 2. Inhibition of the acto-tropomyosin ¢lament motility by the
C-terminal caldesmon fragment H1 (¢lled bars) or H1 phosphoryl-
ated by MAP kinase (dotted bars). Up to 800 ¢laments were auto-
matically analysed in two experiments, each including 3^4 image
processings. Bars indicate the S.D. values.
Fig. 3. Phosphorylation of caldesmon in PDBu-stimulated chicken gizzard strips. (A) Time course of caldesmon phosphorylation. Typical 10%
SDS-PAGE of immunoprecipitates of caldesmon (CD) stained wtih Coomassie (left panel) and the corresponding autoradiogram (right panel)
show a biphasic increase in caldesmon phosphorylation. IgHC and IgLC denote the immunoglobulin heavy and light chains, respectively. The
appearance of an additional radioactive band at the bottom of the autoradiogram is due to caldesmon degradation. (B^D) Autoradiograms of
two-dimensional tryptic phosphopeptide maps of caldesmon phosphorylated in situ in response to vehicle (B) or 2 WM PDBu stimulation for
15 min (C) and 60 min (D). The origin is at the left bottom corner.
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gizzard and treated with 2 WM PDBu for 15 and 60 min (Fig.
3B^D, respectively). The major phosphopeptide spots, as-
signed as 1, 2 and 3, were characteristic for caldesmon from
unstimulated muscle (Fig. 3B) and their intensity increased
with the duration of PDBu treatment. In contrast, the inten-
sities of the spots 4 and X1^X3 increased transiently showing
a maximum at 15 min of PDBu stimulation and reaching 50%
of the total phosphate associated with caldesmon at this time
point. This suggests that phosphorylation of peptides 4 and
X1^X3 is likely to account for the early response to PDBu
observed in Fig. 3A.
To identify the in vivo caldesmon kinases, comparative
phosphopeptide mapping analysis was performed for caldes-
mon immunoprecipitated from PDBu-stimulated gizzard and
chicken gizzard caldesmon phosphorylated in vitro by CK2,
PKCL1/L2, CaMKII and MAP kinase (Fig. 4A^D, respec-
tively). By co-mapping resulting phosphopeptides (data not
shown), the phosphopeptides 1^3 of caldesmon were identi¢ed
as containing MAP kinase phosphorylation sites. An alterna-
tive trypsin digestion and more than one phosphorylation site
for MAP kinase in chicken gizzard caldesmon [20] may ac-
count for multiple generated phosphopeptides, similarly to
that observed for platelet caldesmon [27]. Several radioactive
spots were also detected for each other kinase tested, but none
of them corresponded to phosphopeptides X1^X3 found on
the ’in vivo’ maps of caldesmon (Fig. 4). The phosphopeptide
4 contained the site phosphorylated by PKC (Fig. 4B), but the
fraction of phosphate associated with this site in vivo was
relatively small (Fig. 3).
4. Discussion
PDBu and agonists like endothelin, histamine, etc. have
been found to induce a sustained contraction in vascular
smooth muscle that is associated with considerably less or
even no increase in the intracellular Ca2 concentration com-
pared to that elicited by KCl depolarization [36]. It has been
suggested that such contractions are mediated by Ca2-hyper-
sensitive or even Ca2-independent mechanisms which involve
protein phosphorylation and caldesmon was implicated as one
of the target components of the contractile machinery
[19,35,37]. In a number of smooth muscles, the above-men-
tioned compounds induced an around 2-fold sustained in-
crease in the level of caldesmon phosphorylation, similar to
that obtained for gizzard tissue in this report. However, the
time course of the phosphate incorporation into caldesmon
has not been thoroughly investigated.
We demonstrated here that PDBu stimulates at least two
caldesmon kinases in gizzard smooth muscle in a time-de-
pendent manner (Fig. 3). The sustained phosphorylation is
associated with modi¢cation of MAP kinase phosphorylation
sites in caldesmon (Fig. 4), which con¢rms previously pub-
lished data [14,16,17]. MAP kinase also appears to be the
major caldesmon kinase both in unstimulated tissue and over-
Fig. 4. Autoradiograms of two-dimensional phosphopeptide maps of caldesmon phosphorylated in vitro by CK2 (A), PKC-L (B), CaMKII (C)
and MAP kinase (D). The stoichiometry of phosphorylation was 0.8, 1.2 and 2.4 mol of phosphate per mole of caldesmon, respectively. Num-
bers correspond to the positions of phosphopeptides shown in Fig. 3 and circles denote their positions as separately revealed by co-mapping
(maps not shown).
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stimulated (for 1 h) with PDBu (Fig. 3B, D). Hence, we
searched for the consequences of this phosphorylation on
the caldesmon functional activity and found that it fails to
signi¢cantly reduce the capability of caldesmon to inhibit
the physiologically relevant actin-tropomyosin-activated ATP-
ase of the myosin subfragment (Fig. 1) and therefore weakly
a¡ects the inhibition of the actin ¢lament motility by caldes-
mon in an in vitro motility assay (Fig. 2). Thus, a direct
biochemical support is now provided for the growing physio-
logical evidence that caldesmon phosphorylation by MAP
kinase may not signi¢cantly alter the smooth muscle contrac-
tility [22,24].
For the ¢rst time, we demonstrate here that a kinase addi-
tional to MAP kinase is activated by PDBu and phospho-
rylates caldesmon in vivo (Fig. 3C). The phosphorylated sites
are apparently under a strong phosphatase control which re-
sults in their dephosphorylation despite the continuous stim-
ulation of tissue with PDBu. This yet unidenti¢ed kinase does
not correspond to other well-described enzymes which can
phosphorylate smooth muscle caldesmon in vitro, i.e. PKC,
CaMKII and CK2 (Fig. 4). It neither may be a p34cdc2 kinase,
because it is unlikely to be active in highly di¡erentiated
smooth muscle. PKC was also found to phosphorylate caldes-
mon as it does in non-muscle cells [27], but it has minor
impact in phosphorylation of caldesmon in gizzard (Fig. 3).
It is possible, but seems unlikely, that other PDBu responsive
forms, i.e. ‘novel’ PDCO, may phosphorylate other sites in
caldesmon than the conventional PKCL1/L2 isoform. p21-Ac-
tivated kinase has recently been found to phosphorylate cal-
desmon in vitro and in skinned smooth muscle preparations
[37]. Whether it accounts for the transitory phosphorylation
of caldesmon in gizzard and can be stimulated by PDBu in
vivo is currently under investigation.
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